NCT00506168TerminatedPhase 2
Phase II Study of Irinotecan in Combination With Capecitabine in Previously Untreated Patients With Metastatic Colorectal Cancer
National Cancer Center, Korea2 sites in 2 countries37 target enrollmentStarted: November 2001Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Terminated
- Enrollment
- 37
- Locations
- 2
- Primary Endpoint
- Maximal response rate and toxicities
Study Overview
Brief Summary
This study is to evaluate the efficacy and safety of combination chemotherapy with irinotecan and capecitabine in previously untreated metastatic colorectal cancer.
Detailed Description
This is a single center, single arm, open-label, phase II study to evaluate the efficacy and safety of combination chemotherapy with irinotecan and capecitabine in previously untreated metastatic colorectal cancer.
Patients younger then 65 will be treated with irinotecan 100 mg/m2 on day 1 and 8 and capecitabine 1,000mg/m2 twice daily from day 1 to 14 every 3 weeks.For patiens equal to or older then 65, doses of irinotecan and capecitabine will be reduced to 60 mg/m2 and 750 mg/2, respectively.
Response assessment will be performed every 3 cycles of chemotherapy.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Histologically confirmed metastatic colorectal cancer
- •ECOG performance status 0-2
- •Mesurable lesions
- •No prior chemotherapyk or radiotherapy for metastatic disease. Prior radiotherapy is permitted if it was not administered to target lesions selected for this study and provided it has been completed at least 4 weeks before registration
- •Adjuvnat chemo or radiotherapy was completed at least 6 months prior to start study treatment
- •Adequate organ functions
- •Expected survival is longer then 6 months
- •Informed consent
Exclusion Criteria
- •Prior systemic chemotherapy for metastatic disease
- •Prior treatment with oxaliplatin or irinotecan
- •CNS metastases
- •Uncontrolled or severe cardiovascular disease
- •Serious concurrent infection or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complications of study therapy
- •Other malignancy within the past 3 years except cured non-melanomatous skin cancer or carcinoma in situ of the cervix
- •Psychiatric disorder or uncontrolled seizure that would preclude compliance
- •Pregnant, nursing women or patients with reproductive potential without contraception
- •Patients receiving a concomitant treatment with drugs interacting with capecitabine such as flucytosine, phenytoin, or warfarin et al.
- •Prior unanticipated severe reaction to fluoropyrimidine therapy, or known dihydropyrimidine dehydrogenase (DPD) deficiency
- •Major surgery within 3 weeks prior to study treatment starts, or lack of complete recovery from the effects of major surgery
Outcomes
Primary Outcomes
Maximal response rate and toxicities
Time Frame: During treatment
Secondary Outcomes
- Progression-free survival and overall survival
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Terminated
Phase 2
Docetaxel in Non Small Cell Lung Cancer (NSCLC)Carcinoma, Non-Small-Cell LungNCT00263016Sanofi50
Completed
Phase 2
Irinotecan and Bevacizumab for Recurrent Ovarian CancerFallopian Tube CancerOvarian CancerPrimary Peritoneal CarcinomaNCT01091259NYU Langone Health29
Completed
Phase 2
Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal JunctionGastric AdenocarcinomaStage II Gastric CancerStage III Gastric CancerStage IV Gastric CancerNCT00062374National Cancer Institute (NCI)55
Completed
Phase 2
Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung CancerLung CancerNCT00469898Vanderbilt-Ingram Cancer Center50
Recruiting
Not Applicable
A phase II study of Irinotecan and cisplatin combination chemotherapy in metastatic, unresectable esophageal cancerNeoplasmsKCT0000670Seoul National University Hospital23